High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic LeukemiaStephan Müller, Evelyn Ullrich, Tobias Bexte et al.|Frontiers in Immunology|2020Cited by 111
CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myelomaTobias Bexte, Evelyn Ullrich, Jamal Alzubi et al.|OncoImmunology|2022Cited by 77
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cellsTobias Bexte, Evelyn Ullrich, Nawid Albinger et al.|Nature Communications|2024Cited by 71
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell ImmunotherapyPhilipp Wendel, Evelyn Ullrich, Tobias Bopp et al.|Cancers|2021Cited by 46
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectorsTobias Bexte, Evelyn Ullrich, Lacramioara Botezatu et al.|Molecular Therapy|2024Cited by 44